Novo Nordisk has announced that Wegovy®? (semaglutide injection) will be available for Canadians who meet the requirements in the Health Canada approved product monograph on May 6, 2024. Wegovy®?

will provide additional support for people living with obesity - a serious medical condition. Ongoing high global demand for Wegovy®? speaks to the considerable unmet need for treatment options.

Novo Nordisk will work closely with healthcare providers and regulators to continually assess the level of need along with available supply to help ensure that patients who start treatment can remain on treatment.